Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis

Zrubka, ZsomborGulácsi, LászlóBrodszky, ValentinRencz, FanniAlten, RiekeSzekanecz, ZoltánPéntek, Márta2019-10-252019-10-252019Expert Review of Pharmacoeconomics & Outcomes Research. -19 : 5 (2019), p. 537-549. -Expert Review of Pharmacoeconomics & Outcomes Research. - 1473-7167. - 1744-83791473-71671744-8379http://hdl.handle.net/2437/275040Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysisidegen nyelvű folyóiratközlemény külföldi lapbanopen access articlehttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM081584OrvostudományokKlinikai orvostudományokhttps://www.tandfonline.com/doi/full/10.1080/14737167.2019.1647104http://dx.doi.org/10.1080/14737167.2019.16471042020-02-27